Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes

First Tracks Biotherapeutics witnessed a 20% stock surge following the release of celiac trial data. Simultaneously, Bristol Myers Squibb shares rose significantly due to successes in dual phase 3 clinical trials. Both pharmaceutical companies experienced positive market reactions as investors responded to the latest clinical results. These developments have driven immediate growth for the stocks of First Tracks Biotherapeutics and Bristol Myers Squibb, reflecting strong investor confidence in their respective medical research outcomes.